Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Wednesday the launch of its Nitazoxanide Tablets, 500 mg, the generic version of the reference listed drug Alinia.
Nitazoxanide is used to treat diarrhoea caused by certain parasites.
US annual sales for Nitazoxanide Tablets are approximately USD36.1m, based on the December 2024 moving annual total IQVIA data.
This launch expands ANI's portfolio and provides an alternative treatment option in the market.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream